ArriVent BioPharma Stock Plunges 54% on Disappointing Drug Trial Results
ArriVent BioPharma shares fell 54% to $13 on Tuesday, marking its largest single-day decline, following the release of disappointing results for its lung-cancer drug.
ArriVent BioPharma stock fell sharply on Tuesday after the biopharmaceutical company reported disappointing results for its lung-cancer drug. Shares of ArriVent BioPharma plunged 54% to $13, putting the stock on track for its largest single-day decline on record,